An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (0)
  • Podcast (0)
  • Publications (33)
  • Training (0)
  • User case (0)
  • User meeting (0)
  • Webinar (2)
  • White paper (0)
Key content topics
Key audience
  • Newcomers (0)
Top cancer treatments
  • Brain and CNS (4)
  • Breast (6)
  • Gastro-intestinal (5)
  • Genito-urinary (1)
  • Gynecological (0)
  • Head and neck (12)
  • Hodgkin and Non-Hodgkin lymphoma (0)
  • Ocular (0)
  • Pediatric (4)
  • Reirradiation (8)
  • Sarcomas (1)
  • Thoracic (2)
  • Reset filters
  • (-) Reirradiation

Proton Therapy for Partial Breast Irradiation: Rationale and Considerations.

16/04/2021
/ Publications
/
Reirradiation

A review specifically for PBT partial breast irradiation. This review found that tumor control with PT is excellent, and the toxicities associated with PT PBI...

Proton Therapy in the Management of Pancreatic Cancer.

16/06/2022
/ Publications
/
Dosimetry
Reirradiation
Proton Reirradiation

Although proton treatment plans often showed advantages over photon plans in reducing dose to OARs, the clinical implications were yet to be proven. The key...

Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.

16/06/2022
/ Publications
/
Dosimetry
Reirradiation

Fifteen patients received proton therapy delivered 40.5 GyRBE in 18 fractions to the gross disease and elective nodal volumes followed by 22.5 GyRBE as a 10...

Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer.

16/01/2021
/ Publications
/
Quality of life
Cost management
Reirradiation

Proton therapy was more likely to be cost-effective for patients with p16-positive tumors ($234,201/QALY), compared to p16-negative tumors ($516,297/QALY). For...

Ultra-High Dose-Rate Proton FLASH Improves Tumor Control.

16/09/2023
/ Publications
/
FLASH Therapy
Dosimetry
Reirradiation

This study reported that proton-FLASH (>60 Gy/s) was more effective in reducing tumor burden and decreasing tumor cell proliferation compared conventional...

Pagination

  • Previous page ‹
    • Page 2
    • Page 3
    • Current page 4
Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies